Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial - Archive ouverte HAL Access content directly
Journal Articles PLoS Pathogens Year : 2020

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

(1, 2) , (1) , (3) , (4) , (1) , (2) , (5) , (6) , (3) , (1) , (1) , (7) , (8) , (8) , (1) , (9) , (9) , (9) , (10) , (10) , (11) , (12) , (4) , (13) , (3)
1
2
3
4
5
6
7
8
9
10
11
12
13
Yves Lévy
Christine Lacabaratz
Jean-Daniel Lelièvre
Jonathan Weber
Aurélie Wiedemann
Song Ding
  • Function : Author

Dates and versions

hal-03142733 , version 1 (16-02-2021)

Identifiers

Cite

Yves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, Wolfgang Stöhr, Jean-Daniel Lelièvre, et al.. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. PLoS Pathogens, 2020, 16 (6), pp.e1008522. ⟨10.1371/journal.ppat.1008522⟩. ⟨hal-03142733⟩
26 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More